Saul Priceman: Solid tumor CAR T cells targeting PDL1 for localized IL-12 delivery
Saul Priceman, Associate Professor at City of Hope, shared a post by John P. Murad, Assistant Professor of Research at Keck Medicine of USC, adding:
“Excited for our new BioRxiv preprint on a novel bifunctional fusion protein secreted by CAR T cells that localizes the IL-12 cytokine to solid cancers through binding/blockade of the PDL1 checkpoint pathway.
This T cell engineering strategy shows synergistic anti-tumor efficacy against multiple solid cancers including prostate and ovarian cancers, while safely targeting the potent IL-12 inflammatory cytokine to the tumor microenvironment.
Congrats to John P. Murad, pricemanlab members, Keck Medicine of USC, City of Hope, and our amazing collaborators! Thanks to Prostate Cancer Foundation, private and foundation funds that supported this work.”
Quoting John P. Murad’s post below:
“Very happy that we’re able to finally share part of this great story. Really believe this unique delivery of PDL1 targeting and IL-12 presentation at the tumor can help drive next phase of effective solid tumor targeting CAR T cells.
Grateful to the group of scientists in the pricemanlab at Keck Medicine of USC, City of Hope, and funding and support from private donors and the Prostate Cancer Foundation. Shout out to Lea Christian for her great efforts along the way.
Stay tuned for the full story!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023